You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAmbenonium
Accession NumberDB01122  (APRD00771)
TypeSmall Molecule
GroupsApproved
DescriptionAmbenonium is a cholinesterase inhibitor used in the management of myasthenia gravis. [Wikipedia]
Structure
Thumb
Synonyms
Ambenonium
Ambenonium base
Ambenonum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
MysuranNot Available
MytelaseNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ambenonium chloride
ThumbNot applicableDBSALT001309
Categories
UNIIL16PUN799N
CAS number7648-98-8
WeightAverage: 537.565
Monoisotopic: 536.268482022
Chemical FormulaC28H42Cl2N4O2
InChI KeyInChIKey=OMHBPUNFVFNHJK-UHFFFAOYSA-P
InChI
InChI=1S/C28H40Cl2N4O2/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30/h9-16H,5-8,17-22H2,1-4H3/p+2
IUPAC Name
[(2-chlorophenyl)methyl](2-{[(2-{[(2-chlorophenyl)methyl]diethylazaniumyl}ethyl)carbamoyl]formamido}ethyl)diethylazanium
SMILES
CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC1=CC=CC=C1Cl
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid amides
Alternative Parents
Substituents
  • Alpha-amino acid amide
  • Phenylmethylamine
  • Benzylamine
  • Aralkylamine
  • Halobenzene
  • Chlorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Quaternary ammonium salt
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Organic cation
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationAmbenonium is used to treat muscle weakness due to muscle disease (myasthenia gravis).
PharmacodynamicsAmbenonium, similar to pyridostigmine and neostigmine, is used for the treatment of muscle weakness and fatigue in people with myasthenia gravis. It is postulated to exert its therapeutic effect by enhancing cholinergic function through the inhibition of the acetylcholine hydrolysis by acetylcholinesterase. Increased levels of acetylcholine has peripheral effects, as acetylcholine is also used in the brain, where it tends to cause excitatory actions. The glands that receive impulses from the parasympathetic part of the autonomic nervous system are also stimulated in the same way. This is why an increase in acetylcholine causes a decreased heart rate and increased production of saliva. Ambenonium is used less commonly than neostigmine or pyridostigmine but may be preferred in patients hypersensitive to the bromide ion. Ambenonium produces fewer muscarinic side effects than neostigmine, but more than pyridostigmine.
Mechanism of actionAmbenonium exerts its actions against myasthenia gravis by competitive, reversible inhibition of acetylcholinesterase. The disease myasthenia gravis occurs when the body inappropriately produces antibodies against acetylcholine receptors, and thus inhibits proper acetylcholine signal transmission (when acetylcholine binds to acetylcholine receptors of striated muscle fibers, it stimulates those fibers to contract). Ambenonium reversibly binds acetylcholinesterase at the anionic site, which results in the blockage of the site of acetycholine binding, thereby inhibiting acetylcholine hydrolysis and enhancing cholinergic function through the accumulation of acetycholine at cholinergic synpases. In turn this facilitates transmission of impulses across the myoneural junction and effectively treats the disease.
Related Articles
AbsorptionOral - poorly absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Plasma and hepatic

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityLD50=150±44 mg/kg (orally in mice). Symptoms of overdose include muscle twitching, weakness and paralysis of voluntary muscles including the tongue, shoulders, neck and arms, blood pressure increase (with or without a slowing of heart rate), a sensation of internal trembling, severe anxiety, and panic. Death may occur rapidly if untreated.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9618
Blood Brain Barrier+0.8373
Caco-2 permeable+0.5168
P-glycoprotein substrateSubstrate0.8725
P-glycoprotein inhibitor INon-inhibitor0.6717
P-glycoprotein inhibitor IINon-inhibitor0.766
Renal organic cation transporterNon-inhibitor0.823
CYP450 2C9 substrateNon-substrate0.7865
CYP450 2D6 substrateNon-substrate0.7008
CYP450 3A4 substrateSubstrate0.5842
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.6899
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.538
Ames testNon AMES toxic0.7312
CarcinogenicityNon-carcinogens0.6118
BiodegradationNot ready biodegradable0.9927
Rat acute toxicity2.4379 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9665
hERG inhibition (predictor II)Inhibitor0.8507
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Mytelase 10 mg caplet1.86USD caplet
Mytelase 10 mg tablet1.86USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point196-199 °CKirchner, F.K.; U.S. Patent 3,096,373; July 2,1963; assigned to Sterling Drug Inc.
water solubilitySolubleNot Available
Predicted Properties
PropertyValueSource
Water Solubility9.42e-07 mg/mLALOGPS
logP2.27ALOGPS
logP-3.6ChemAxon
logS-8.8ALOGPS
pKa (Strongest Acidic)10.78ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.2 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity173.57 m3·mol-1ChemAxon
Polarizability59.98 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Kirchner, F.K.; U.S. Patent 3,096,373; July 2,1963; assigned to Sterling Drug Inc.

General ReferencesNot Available
External Links
ATC CodesN07AA30
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (166 KB)
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Ambenonium.
AcebutololAmbenonium may increase the bradycardic activities of Acebutolol.
AcetylcholineThe risk or severity of adverse effects can be increased when Ambenonium is combined with Acetylcholine.
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Ambenonium.
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Ambenonium.
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Ambenonium.
AlprenololAmbenonium may increase the bradycardic activities of Alprenolol.
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Ambenonium.
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Ambenonium.
ArecolineThe risk or severity of adverse effects can be increased when Ambenonium is combined with Arecoline.
ArotinololAmbenonium may increase the bradycardic activities of Arotinolol.
AtenololAmbenonium may increase the bradycardic activities of Atenolol.
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Ambenonium.
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Ambenonium.
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Ambenonium.
BefunololAmbenonium may increase the bradycardic activities of Befunolol.
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Ambenonium.
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Ambenonium.
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Ambenonium.
BetaxololAmbenonium may increase the bradycardic activities of Betaxolol.
BethanecholThe risk or severity of adverse effects can be increased when Ambenonium is combined with Bethanechol.
BevantololAmbenonium may increase the bradycardic activities of Bevantolol.
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Ambenonium.
BisoprololAmbenonium may increase the bradycardic activities of Bisoprolol.
BopindololAmbenonium may increase the bradycardic activities of Bopindolol.
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Ambenonium.
BufuralolAmbenonium may increase the bradycardic activities of Bufuralol.
BupranololAmbenonium may increase the bradycardic activities of Bupranolol.
CarbacholThe risk or severity of adverse effects can be increased when Ambenonium is combined with Carbachol.
CarteololAmbenonium may increase the bradycardic activities of Carteolol.
CarvedilolAmbenonium may increase the bradycardic activities of Carvedilol.
CeliprololAmbenonium may increase the bradycardic activities of Celiprolol.
CevimelineThe risk or severity of adverse effects can be increased when Ambenonium is combined with Cevimeline.
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Ambenonium.
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Ambenonium.
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Ambenonium.
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Ambenonium.
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Ambenonium.
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Ambenonium.
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Ambenonium.
DehydroepiandrosteroneThe risk or severity of adverse effects can be increased when Dehydroepiandrosterone is combined with Ambenonium.
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Ambenonium.
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Ambenonium.
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Ambenonium.
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Ambenonium.
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Ambenonium.
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Ambenonium.
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Ambenonium.
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Ambenonium.
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Ambenonium.
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Ambenonium.
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Ambenonium.
DipyridamoleThe therapeutic efficacy of Ambenonium can be decreased when used in combination with Dipyridamole.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Ambenonium is combined with EPIBATIDINE.
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Ambenonium.
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Ambenonium.
EsmololAmbenonium may increase the bradycardic activities of Esmolol.
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Ambenonium.
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Ambenonium.
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Ambenonium.
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ambenonium.
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Ambenonium.
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Ambenonium.
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Ambenonium.
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Ambenonium.
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Ambenonium.
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Ambenonium.
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Ambenonium.
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Ambenonium.
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Ambenonium.
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Ambenonium.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Ambenonium.
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Ambenonium.
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Ambenonium.
GTS-21The risk or severity of adverse effects can be increased when Ambenonium is combined with GTS-21.
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Ambenonium.
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Ambenonium.
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ambenonium.
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Ambenonium.
IndenololAmbenonium may increase the bradycardic activities of Indenolol.
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Ambenonium.
LabetalolAmbenonium may increase the bradycardic activities of Labetalol.
LobelineThe risk or severity of adverse effects can be increased when Ambenonium is combined with Lobeline.
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Ambenonium.
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Ambenonium.
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Ambenonium.
MethacholineThe risk or severity of adverse effects can be increased when Ambenonium is combined with Methacholine.
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Ambenonium.
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ambenonium.
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Ambenonium.
MetoprololAmbenonium may increase the bradycardic activities of Metoprolol.
MivacuriumAmbenonium may decrease the neuromuscular blocking activities of Mivacurium.
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Ambenonium.
N-butylscopolammonium bromideThe therapeutic efficacy of N-butylscopolammonium bromide can be decreased when used in combination with Ambenonium.
NadololAmbenonium may increase the bradycardic activities of Nadolol.
NicotineThe risk or severity of adverse effects can be increased when Ambenonium is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Ambenonium is combined with Nicotine bitartrate.
NVA237The therapeutic efficacy of NVA237 can be decreased when used in combination with Ambenonium.
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Ambenonium.
OxprenololAmbenonium may increase the bradycardic activities of Oxprenolol.
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Ambenonium.
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Ambenonium.
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Ambenonium.
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Ambenonium.
PenbutololAmbenonium may increase the bradycardic activities of Penbutolol.
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Ambenonium.
PilocarpineThe risk or severity of adverse effects can be increased when Ambenonium is combined with Pilocarpine.
PindololAmbenonium may increase the bradycardic activities of Pindolol.
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Ambenonium.
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Ambenonium.
PractololAmbenonium may increase the bradycardic activities of Practolol.
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Ambenonium.
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ambenonium.
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Ambenonium.
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Ambenonium.
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Ambenonium.
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Ambenonium.
PropranololAmbenonium may increase the bradycardic activities of Propranolol.
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Ambenonium.
RapacuroniumAmbenonium may decrease the neuromuscular blocking activities of Rapacuronium.
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Ambenonium.
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Ambenonium.
Scopolamine butylbromideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Ambenonium.
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Ambenonium.
SotalolAmbenonium may increase the bradycardic activities of Sotalol.
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Ambenonium.
TimololAmbenonium may increase the bradycardic activities of Timolol.
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Ambenonium.
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Ambenonium.
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Ambenonium.
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Ambenonium.
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Ambenonium.
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Ambenonium.
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Ambenonium.
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Ambenonium.
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Ambenonium.
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Ambenonium.
VareniclineThe risk or severity of adverse effects can be increased when Ambenonium is combined with Varenicline.
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Ambenonium.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine hydrolase activity
Specific Function:
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name:
ACHE
Uniprot ID:
P22303
Molecular Weight:
67795.525 Da
References
  1. Lockhart B, Closier M, Howard K, Steward C, Lestage P: Differential inhibition of [3H]-oxotremorine-M and [3H]-quinuclinidyl benzilate binding to muscarinic receptors in rat brain membranes with acetylcholinesterase inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2001 Apr;363(4):429-38. [PubMed:11330337 ]
  2. Hodge AS, Humphrey DR, Rosenberry TL: Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities. Mol Pharmacol. 1992 May;41(5):937-42. [PubMed:1588924 ]
  3. Papp MI, Komoly S, Szirmai IG, Kovacs T: Similarities between CSF-brain extracellular transfer and neurofibrillary tangle invasion in Alzheimer's disease. Neurobiol Aging. 2006 Mar;27(3):402-12. Epub 2005 Jun 27. [PubMed:15982786 ]
  4. Kenakin TP, Beek D: Self-cancellation of drug properties as a mode of organ selectivity: the antimuscarinic effects of ambenonium. J Pharmacol Exp Ther. 1985 Mar;232(3):732-40. [PubMed:2857786 ]
  5. Webb GD: Affinity of benzoquinonium and ambenonium derivatives for the acetylcholine receptor, tested on the electroplax, and for acetylcholinesterase in solution. Biochim Biophys Acta. 1965 May 25;102(1):172-84. [PubMed:5833399 ]
  6. Bolognesi ML, Cavalli A, Andrisano V, Bartolini M, Banzi R, Antonello A, Rosini M, Melchiorre C: Design, synthesis and biological evaluation of ambenonium derivatives as AChE inhibitors. Farmaco. 2003 Sep;58(9):917-28. [PubMed:13679187 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Yamamoto K, Kohda Y, Sawada Y, Iga T: Pharmacokinetics of ambenonium, a reversible cholinesterase inhibitor, in rats. Biopharm Drug Dispos. 1991 Nov;12(8):613-25. [PubMed:1801966 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23